Drug intelligence / Profile preview

yiqi weixue

Development stage: Unknown
Lead developer: Red Coral Pharmaceutical
Administration: Oral

Overview

Yiqi Weixue is a Traditional Chinese Medicine (TCM) product developed by Guangdong Hongshanhu Pharmaceutical, primarily indicated for the treatment of iron deficiency anemia and syndromes characterized by deficiency of both qi and blood. The formulation typically contains heme iron extracted from porcine blood, combined with herbal extracts such as Astragalus membranaceus (Huangqi) and Ziziphus jujuba (Dazao). It acts by supplementing iron directly and utilizing herbal components to tonify qi, which in TCM theory supports the production and circulation of blood. It is available in several oral dosage forms, including capsules, granules, and oral liquids, and is widely used in China as a blood tonic.

Brand names: Yixuebao
Other names: Yiqi Weixue JiaonangYiqi Weixue KeliYiqi Weixue Koufuye益气维血益气维血胶囊益气维血颗粒

Beyond the preview

Go deeper on yiqi weixue.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on yiqi weixue.

Explore the full profile